In a urinary culture positive for multidrug‑resistant Pseudomonas aeruginosa that is only susceptible to fosfomycin, amikacin, and gentamicin, which antibiotic should be chosen as the primary therapy?

Treatment of MDR Pseudomonas aeruginosa UTI with Limited Susceptibility Options

For a urinary culture positive for multidrug-resistant Pseudomonas aeruginosa susceptible only to fosfomycin, amikacin, and gentamicin, choose amikacin 15 mg/kg IV once daily as primary therapy. 1

Rationale for Amikacin Selection

The 2024 European Association of Urology guidelines explicitly list amikacin at 15 mg/kg once daily as a recommended parenteral agent for treating complicated UTIs, including those caused by multidrug-resistant organisms 1. This is the most direct guideline-based recommendation available for your clinical scenario.

Why Amikacin Over Gentamicin

While both aminoglycosides are listed in the EAU guidelines, amikacin offers several advantages:

• Higher tissue penetration: Amikacin achieves better urinary concentrations at the recommended dosing
• Broader activity against resistant Pseudomonas: Recent surveillance data shows amikacin maintains better susceptibility rates (43-78%) compared to gentamicin (45%) against MDR Pseudomonas 2, 3
• Less cross-resistance: Amikacin-modifying enzymes are less prevalent than those affecting gentamicin

Why Not Fosfomycin Monotherapy

Critical limitation: The EAU guidelines explicitly state that oral fosfomycin "should be avoided as there are insufficient data regarding their efficacy" for pyelonephritis 1. The FDA label confirms fosfomycin is only indicated for uncomplicated cystitis in women 4. While IV fosfomycin exists and is mentioned for MDR organisms 5, it's not widely available and the guidelines note "insufficient evidence" for monotherapy in severe infections.

Optimal Treatment Strategy

For Complicated UTI/Pyelonephritis:

• Primary choice: Amikacin 15 mg/kg IV once daily 1
• Duration: 7-14 days depending on clinical response
• Monitor: Renal function and drug levels (target peak 55-60 mcg/mL, trough <5 mcg/mL)

Consider Combination Therapy If:

The patient has severe sepsis, bacteremia, or is critically ill. In these scenarios, amikacin + fosfomycin combination demonstrates synergistic activity against MDR Pseudomonas 6, 7, 8:

• Fosfomycin/amikacin showed 92% efficacy against multiresistant Pseudomonas serotype O12 7
• Synergistic effects demonstrated both in vitro and in biofilm-infected animal models 6
• Combination therapy significantly superior to monotherapy for biofilm inhibition 8

Dosing for combination:

• Amikacin 15 mg/kg IV once daily
• IV fosfomycin (if available): 4-8g IV every 8 hours
• Oral fosfomycin is NOT appropriate for this indication

Critical Pitfalls to Avoid

1. Don't use oral fosfomycin for anything beyond uncomplicated cystitis - The guidelines are clear this lacks efficacy data for upper tract infections 1

2. Don't use gentamicin as monotherapy for pyelonephritis - The EAU guidelines note it's "not studied as monotherapy in acute uncomplicated pyelonephritis" 1

3. Avoid nephrotoxicity - Once-daily aminoglycoside dosing reduces toxicity while maintaining efficacy. Monitor creatinine every 2-3 days 2

4. Source control is mandatory - If obstruction, stones, or foreign bodies are present, drainage/removal is essential for treatment success 9

Supporting Evidence Quality

The recommendation prioritizes the 2024 EAU guidelines 1 as the highest-quality, most recent guideline evidence. These are augmented by:

• 2022 ESCMID guidelines supporting aminoglycosides for non-severe cUTI caused by carbapenem-resistant organisms 5
• Recent clinical data (2022) showing aminoglycoside monotherapy non-inferior to other regimens for XDR-Pseudomonas cUTI 2
• Multiple studies demonstrating fosfomycin-aminoglycoside synergy 6, 7, 8

The convergence of guideline recommendations, FDA labeling, and clinical outcomes data strongly supports amikacin as the primary choice in this challenging scenario.